Form 4: Regeneron Director Kathryn Guarini Acquires Equity

Regeneron Pharmaceuticals director Kathryn Guarini acquired 155 restricted stock units and 1,962 non-qualified stock options on January 2, 2026.

Summary

• Kathryn Guarini, a Director of Regeneron Pharmaceuticals, Inc. (REGN), acquired 155 shares of common stock through time-based vesting restricted stock units (RSUs).
• She also acquired 1,962 non-qualified stock options with an exercise price of $772.76.
• The RSUs and stock options were granted on January 2, 2026.
• Following these transactions, Guarini directly beneficially owns 603 shares of common stock and 1,962 derivative securities (stock options).
• The stock options will become exercisable in portions, starting on the date of the Issuer's first annual meeting of shareholders following the grant date, with the remainder exercisable on the first anniversary of the grant date, and expire on January 2, 2036.

Sentiment

Score: 7

Explanation: The filing indicates a routine equity grant to a director, which is a positive for aligning interests and incentivizing long-term performance. It's a standard corporate governance practice and doesn't suggest any negative operational or financial issues.

Positives

• Increased insider ownership aligns the director's interests with shareholders.
• The grant of stock options provides a long-term incentive for performance.
• The acquisition of RSUs and stock options at a $0.0 price indicates a compensation grant, which is a common practice for director compensation.

Future Outlook

NA

Industry Context

This is a routine insider transaction for director compensation, common across the pharmaceutical and biotechnology industries, aiming to align executive and director interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units and stock options as part of director compensation is a standard practice in publicly traded companies, particularly within the pharmaceutical sector, to incentivize long-term performance and retention.
• The specific number of units and options granted would typically be benchmarked against peer companies of similar market capitalization and industry within the S&P 500 or relevant industry indices to ensure competitive compensation.
• Companies like Pfizer, Merck, and Johnson & Johnson often utilize similar equity-based compensation structures for their non-executive directors, though the specific values and vesting schedules vary based on company size, performance, and compensation philosophy.

Corporate Governance

Related Party Transactions

• Acquisition of 155 restricted stock units and 1,962 non-qualified stock options by Kathryn Guarini, a Director of Regeneron Pharmaceuticals, Inc., from the Issuer.

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with long-term shareholder value through equity ownership and incentives.
• Employees: No direct impact on general employees, but reflects standard compensation practices for leadership.

Next Steps

• The stock options will become exercisable in portions, starting on the date of the Issuer's first annual meeting of shareholders following the grant date, with the remainder exercisable on the first anniversary of the grant date.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a director as part of their compensation. It signifies alignment of interests between the director and shareholders but does not provide new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in an investment recommendation. It's a standard governance disclosure.

Keywords

Regeneron Pharmaceuticals, REGN, Kathryn Guarini, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director Compensation, Equity Grant, Beneficial Ownership